Investing in BeiGene, Ltd. (BGNE)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)45219.9827771
Intrinsic value (DCF)38780.9223802
Graham-Dodd Method0.00-100
Graham Formula0.00-100

Company description

BeiGene (BGNE) is a leading biotechnology company that focuses on developing innovative therapies for cancer and other serious diseases. The company was founded in 2010 and has since grown to become a global player in the biopharmaceutical industry. By utilizing cutting-edge scientific approaches, BeiGene has successfully developed a diverse portfolio of drug candidates that target a wide range of cancers, including solid tumors and blood cancers. The company's flagship product, BGB-A317, has shown excellent results in clinical trials and has received breakthrough therapy designation from the FDA for the treatment of classical Hodgkin's lymphoma. BeiGene's commitment to advancing cancer treatment is further demonstrated by its collaboration with major pharmaceutical companies, such as Amgen and Novartis, to co-develop and commercialize its pipeline drugs. With a strong presence in both China and the US, BeiGene is well-positioned to expand its global reach and make a significant impact in the fight against cancer.